Trial Profile
Randomized, multicenter, double-blind, phase 3 trial of Tavocept versus Placebo in patients with newly diagnosed or relapsed advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with docetaxel or paclitaxel plus cisplatin.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Jul 2019
Price :
$35
*
At a glance
- Drugs Dimesna (Primary) ; Cisplatin; Docetaxel; Paclitaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors BioNumerik Pharmaceuticals
- 16 May 2014 New source identified and integrated (ClinicalTrials.gov; NCT00966914).
- 22 Apr 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 16 Nov 2011 Actual initiation date (21 Oct 2009) added as reported by European Clinical Trials Database.